EASI Access II --- Follow-up Study to the EASI Access Trial

Completed · Phase 1

Conditions studied: Disaster Medicine, Difficult Intravenous Access, Dehydration

In brief

Test whether Basic Life Support (BLS) providers can successfully place Enzymatically Augmented Subcutaneous Infusion (EASI) Access lines for subcutaneous infusion, and characterize intravascular absorption of EASI-administered (tracer-labelled) glucose (D5W).

Key facts

Study ID

NCT00740727

Run by

Massachusetts General Hospital

People needed

18

Starts

2009-02-01

Expected to finish

2009-03-01

Last updated by the study team

2009-09-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects will be at least 18 years of age and have none of the following conditions:
• pregnancy (negative urine pregnancy test to be performed before study participation),
• diabetes, or coagulopathic (including taking any anticoagulants);
• Subjects cannot be taking steroids or other immunosuppressants.
• Because of the potential for reduced hyaluronidase effectiveness, the study excludes patients taking more than 80 mg daily aspirin, as well as any patients taking ACTH, antihistamines, or estrogen other than in oral contraceptive preparations.
• Subjects will not be required to fast before the study, but will not allowed to eat or drink during the EASI infusion or the phlebotomy sampling time frame.

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.